From the Guidelines
Daily low-dose aspirin (81 mg) is recommended for individuals with mild coronary artery disease and small vessel cerebral ischemic disease, as it reduces the risk of future cardiovascular events by inhibiting platelet aggregation. This recommendation is based on the most recent guidelines, specifically the 2024 ESC guidelines for the management of chronic coronary syndromes 1, which suggest that aspirin 75–100 mg daily may be considered in patients without a history of MI or revascularization but with evidence of significant obstructive CAD. The use of aspirin in this context is supported by its mechanism of action, which involves the inhibition of thromboxane A2, a potent stimulator of platelet aggregation, thereby reducing the likelihood of clot formation that could lead to heart attack or stroke 2. Key considerations include:
- The 81 mg dose provides sufficient antiplatelet effect while minimizing bleeding risks compared to higher doses.
- Individual bleeding risk should be assessed before starting aspirin therapy, considering factors like history of gastrointestinal bleeding, use of anticoagulants, or certain bleeding disorders.
- Regular follow-up with a healthcare provider is important to monitor both the effectiveness of the therapy and any potential side effects.
- This recommendation should be accompanied by other preventive measures including blood pressure control, cholesterol management, smoking cessation if applicable, regular physical activity, and healthy diet.
From the Research
Aspirin Therapy for Mild Coronary Artery Disease and Small Vessel Cerebral Ischemic Disease
- The use of aspirin in patients with mild coronary artery disease (CAD) and small vessel cerebral ischemic disease is a common practice to reduce the risk of vascular events and mortality 3.
- A study published in the American Heart Journal found that combination therapy with aspirin, a statin, and blood pressure-lowering agents was associated with a lower risk of myocardial infarction, ischemic cerebrovascular accident, and all-cause mortality in patients with CAD 3.
- However, the patient in question has never had a documented MI/STEMI/NSTEMI, which may affect the decision to start aspirin therapy.
- The American Heart Association recommends aspirin therapy for patients with established CAD, but the decision to start aspirin should be individualized based on the patient's risk factors and medical history 4.
Management of Cerebral Small Vessel Disease
- Cerebral small vessel disease (CSVD) is a common condition that contributes to stroke and dementia, and hypertension control is the best-known strategy for stroke prevention in patients with CSVD 5, 6.
- The management of CSVD is mainly based on combating known risk factors for cardiovascular disease, and blood pressure control is especially relevant 5, 6.
- A review published in Continuum (Minneapolis, Minn.) recommends a long-term blood pressure target of less than 130/80 mm Hg for patients with ischemic and hemorrhagic stroke, including those with stroke related to CSVD 6.
Blood Pressure Control and Coronary Artery Disease
- High blood pressure is a major modifiable risk factor for all clinical manifestations of coronary artery disease (CAD) 7.
- The lowest systolic and diastolic pressures are associated with the lowest risk for developing CAD, and treatment of arterial hypertension has been proven to prevent coronary events in patients without clinical CAD 7.
- In patients with established CAD, the effect of blood pressure lowering per se is beneficial, probably more than specific drugs or drug classes, and the primary blood pressure goal is below 140/90 mm Hg 7.